Dietary supplementation with fish gelatine modifies nutrient intake and leads to sex-dependent responses in TAG and C-reactive protein levels of insulin-resistant subjects

Éliane Picard-Deland1,2, Charles Lavigne1,3, Julie Marois1,2, Julie Bisson1,2, S. John Weisnagel4,5, André Marette1,3, Bruce Holub6, Eugene Chu7, Jiri Frohlich7, John S. Hill7 and Hélène Jacques1,2*

Institute of Nutraceuticals and Functional Foods, Quebec, Canada G1V 0A6
2 Department of Food Science and Nutrition, Quebec, Canada G1V 0A6
3 Department of Medicine, Faculty of Medicine, Cardiology Axis of the Institut Universitaire de Cardiologie et de Pneumologie de Québec (Hôpital Laval) and Metabolism, Vascular and Renal Health Axis, Quebec, Canada G1V 4G5
4 Department of Social and Preventive Medicine, Division of Kinesiology, Laval University, Quebec, Canada G1V 0A6
5 Diabetes Research Unit, Lipid Research Center, Laval University Hospital Research Center, Quebec, Canada G1V 4G2
6 Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Canada N1G 2W1
7 UBC James Hogg Research Centre, Institute for Heart and Lung Health and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada V6Z 1Y6

(Received 17 October 2011 – Final revision received 29 June 2012 – Accepted 19 July 2012)

Abstract

Over the last few decades, dyslipidaemia and chronic low-grade inflammation associated with obesity have been described as key features of obesity-related insulin resistance, CVD and type 2 diabetes.(1)

Abbreviations: FG, fish gelatine; hsCRP, highly sensitive C-reactive protein.

* Corresponding author: Hélène Jacques, fax +418 656 3353, email helene.jacques@fsaa.ulaval.ca

© The Author(s) 2012. The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/2.5/>. The written permission of Cambridge University Press must be obtained for commercial re-use.
HDL-cholesterol(2). Furthermore, it has been proposed that dietary n-3 PUFA can reduce low-grade inflammatory state by modulating the eicosanoid system and the transcription factors NF-κB and PPAR(3). Indeed, increasing evidence shows that the ingestion of EPA and DHA in human subjects may reduce the secretion of pro-inflammatory cytokines, e.g. IL-6, TNF-α, and monocyte chemoattractant protein-1, by adipocytes and macrophages(4). However, other intervention trials have not confirmed these effects(5,6) and these studies using n-3 fatty acid supplementation have failed to show any effect on the levels of systemic pro-inflammatory cytokine C-reactive protein(5,6) even though the fish oil supplement was given at a high dose(7).

CVD risk factors and type 2 diabetes have also been shown to be strongly influenced by energy intake and weight loss. Thus, the optimal macronutrient composition of a diet that facilitates lasting and safe weight loss and that improves markers of CVD risk factors remains an area of great controversy(7). Interestingly, increasing the amount of protein may positively influence the regulation of food intake by improving satiety and modulating energy balance(8,9). Besides, there has also been interest in the effect of various types of proteins on the modulation of CVD risk factors.

Fish protein has indeed been shown to induce beneficial effects on insulin sensitivity(10,11), blood lipids(12-15) and systemic inflammation(16,17). In comparison with other animal proteins, fish protein has been shown to modulate lipid profile by decreasing VLDL TAG in pre- and post-menopausal females(12,13), and increasing HDL2-cholesterol in normocholesterolaemic(14) and hypercholesterolaemic males(15). In addition, we(16) and others(17) recently observed that highly sensitive C-reactive protein (hsCRP) is reduced following a lean fish diet. The effects of fish protein on CVD risk factors have been proposed to be due, at least in part, to its unique amino acid profile rich in glycine, taurine and arginine. On the other hand, one of our previous studies(18) showed that fish protein and menhaden oil exerted additive and independent effects on plasma TAG metabolism in the rat. In that study the combination of cod protein and menhaden oil lowered plasma TAG by 50 %. In recent years, there has been growing interest in studying the properties of fish gelatine (FG)(19), composed of peptides and amino acids resulting from collagen hydrolysis. Indeed, there is increasing evidence for the use of collagen hydrolysate supplementation for patients with inflammatory disease(20), and it has been shown that ingestion of collagen may have hypolipidaemic effects in animals(21,22). However, there is little information about the effects of FG supplementation on lipid profile and inflammatory and CVD markers in human subjects.

Based on evidence indicating that marine n-3 PUFA and fish protein could independently reduce CVD markers, this study was designed to compare the combined effects of a FG and n-3 PUFA supplement with those of an n-3 PUFA supplement on (1) energy intake and body weight, (2) lipid profile and (3) inflammatory and CVD markers in free-living insulin-resistant subjects. We hypothesised that the FG supplement would reduce energy intake and body weight and improve the effects of marine n-3 PUFA on blood lipids, cytokines and CVD indicators in insulin-resistant males and females. As there is considerable evidence that sex hormones may modulate food intake, body weight(23) and lipid and inflammatory metabolism(24), we further explored possible sex differences in the effect of FG on those parameters.

Experimental methods

Subjects

A total of twenty-one subjects, ten males and eleven females, aged 35–70 years, were recruited in the Quebec City area by media advertising. All subjects completed a medical evaluation, including routine laboratory testing and a 75 g oral glucose tolerance test. Individuals were eligible if they were overweight or obese (BMI > 25 kg/m²) and were insulin-resistant with high fasting plasma insulin(25) corresponding to the percentile above the 75th for fasting insulin levels in a sample from the adult Quebec population(26), and/or had impaired fasting plasma glucose (5.6–6.9 mmol/l), and/or had impaired glucose tolerance following 2 h post 75 g oral glucose tolerance test with plasma glucose corresponding to 7.8–11.0 mmol/l(27). Exclusion criteria included weight change ± 10 % within the 6 months that preceded the study, major surgery in the 3 months prior to study onset, diabetes, familial or primary hyperlipidaemia, hepatic or metabolic diseases, smoking, chronic hypertension (>160/100 mmHg), incompatibility with fish consumption (allergy, intolerance or dislike), and medications known to affect the lipid and glucose metabolism.

This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by the Clinical Research Ethical Committee of Laval University Hospital Center. After the experimental protocol was explained with precaution, written informed consent was obtained from all subjects.

Experimental design

A crossover design with two experimental periods of 8 weeks was used. After a 4-week run-in period, either an n-3 PUFA supplement alone or an n-3 PUFA supplement plus FG incorporated into a broth (n-3 PUFA + FG) was administered randomly to the subjects. At the end of the first experimental period, participants returned to their usual diet for a washout period of 12 weeks, including a second 4-week run-in period. Then, the participants crossed over to the other experimental diet for an additional 8 weeks. During the 4-week run-in periods, the participants were asked not to consume products that contained marine n-3 PUFA, to maintain their regular food habits and their physical activity level and to refrain from alcohol consumption (not more than one drink per d for females and two drinks per d for males).

Diets

The n-3 PUFA supplement provided during the n-3 PUFA and the n-3 PUFA + FG supplements corresponded to 1.8 g of EPA and DHA per d in a 2:1 ratio (capsules provided by
Ocean Nutrition Canada). The FG supplement provided during the n-3 PUFA + FG treatment corresponded to approximately 25% of the participant’s daily protein consumption and was incorporated into a chicken broth. A high-molecular-weight food/pharmaceutical-grade FG (Norland Products) produced from the hydrolysis of collagen was used to prepare the FG broth. It was produced from lean fish skins, mainly from cod, pollock and haddock. Amino acid analyses of the FG were performed at Quebec’s Aquaculture and Fisheries Innovation Centre, Quebec, using a technique previously described by Beaulieu et al. Briefly, a pre-column derivatisation technique, the AccQ-Tag amino acid analysis procedure (Waters), was used for the measurement of amino acids resistant to acidic hydrolysis. The amino acids were separated by reversed-phase HPLC and quantified using fluorescence detection. The amino acid composition of FG is shown in Table 1.

The FG broth was prepared at the metabolic kitchen of the Institute of Nutraceuticals and Functional Foods of Laval University and was provided daily to the subjects. The FG broth was consumed in different recipes at home by the participants. Compliance was assessed from the return of capsules and containers and uneaten FG broth to determine the quantity consumed, from 24 h recalls every 2 weeks and from a FFQ administrated by a dietitian, at the beginning and at the end of each experimental period. The energy and nutrient intake information derived from compilation of the FFQ was analysed using nutrient composition values from the Nutrition Data System for Research software version 4.03 (University of Minnesota, Minneapolis, MN, Food and Nutrient Database, 2000). Moreover, participants were asked to fill in a 3-d diary (two weekdays and one weekend day) during each experimental period. All participants consumed more than 80% of the FG broth and more than 85% of the n-3 PUFA supplements.

The compliance for FG and n-3 PUFA supplements was more than 95% for fourteen subjects.

### Clinical and laboratory measurements

#### Anthropometric measurements

Height was measured with a stadiometer at the beginning of the study. Before and after each treatment, waist circumference and hip circumference were measured in duplicate. Waist circumference was measured at the level midway between the lowest rib margin and the iliac crest, and hip circumference was measured at the broadest circumference below the waist. Weight was recorded at the beginning and at the end of the two experimental periods, and at mid-period during each experimental period using a digital scale while subjects were barefoot. BMI was calculated as weight (in kg) divided by height (in metres) squared.

#### Blood collection

Blood samples were drawn after a 12 h overnight fast from an antecubital vein, before and after each experimental treatment. Blood samples were centrifuged immediately at 3000 g for 10 min at 4°C to separate plasma and serum, which were stored at −80°C until further measurements of inflammatory marker and lipid concentrations.

#### Inflammatory and cardiovascular marker concentrations

Inflammatory and cardiovascular marker concentrations were measured in serum, at the Laval University Hospital Center, Quebec, using commercially available methods as follows: the immunoassay Lumines xMAP Multiplexing (Millipore) was used to measure IL-6, monocyte chemotactic protein-1, TNF-α, adiponectin and myeloperoxidase. IL-1β (Invitrogen) and IL-1 receptor antagonist (Invitrogen) were measured using an ulrasensitive ELISA kit. IL-10 (Invitrogen), serum amyloid A (Invitrogen) and asymmetric dimethylarginine (ALPCO) were measured using an ELISA kit.

Other biomarker concentrations were measured at the Atherosclerosis Specialty Laboratory at St Paul’s Hospital, Vancouver, using commercially available methods as follows: leptin (R&D Systems) was measured using an ELISA kit in serum. Plasminogen activator inhibitor-1 (R&D Systems) and resistin (R&D Systems) were measured using ELISA kits in plasma. hsCRP was measured in serum using the CardioPhase hsCRP immunonephelometry technique (Siemens Healthcare Diagnostics Products). Homocysteine was measured in plasma using an ADVIA Centor HCY assay (Bayer Healthcare LLC), based on a competitive immunoassay and direct chemiluminescent technique.

#### Plasma lipid and lipoprotein concentrations

Plasma VLDL (<1-006 g/ml) were removed from plasma using a ultracentrifugation technique as previously reported by Moorjani et al. LDL was precipitated with heparin and MnCl₂ and HDL particles were isolated from the bottom fraction (>1-006 g/ml). Cholesterol and TAG concentrations

---

**Table 1. Amino acid composition of fish gelatine (FG)**

| Amino acids     | FG (g/100 g of amino acids) |
|-----------------|----------------------------|
| Aspartic acid   | 6.40                       |
| Serine          | 6.06                       |
| Glutamic acid   | 10.0                       |
| Glycine         | 21.5                       |
| Histidine       | 2.09                       |
| Taurine         | 0.40                       |
| Arginine        | 7.50                       |
| Threonine       | 2.66                       |
| Alanine         | 8.57                       |
| Proline         | 9.90                       |
| Cysteine        | 0.67                       |
| Tyrosine        | 0.71                       |
| Valine          | 1.68                       |
| Methionine      | 1.93                       |
| Lysine          | 3.91                       |
| Isoleucine      | 1.01                       |
| Leucine         | 2.20                       |
| Phenylalanine   | 1.84                       |

* Provided by Norland Products Inc. (Kenney and Ross Limited).
† Amino acid measurements were carried out at Quebec’s Aquaculture and Fisheries Innovation Centre, Quebec, using the technique previously described by Beaulieu et al.
‡ Values are the means of two determinations.
were determined enzymatically by using a Technicon RA-500 analyzer (Bayer).

**Statistical analyses**

The *a posteriori* power of the study was calculated using the collected data from this study. On the basis of those data, the present study had a power of 0.73 to detect a 20% decrease in our main outcome plasma TAG (at a two-sided α-level of 0.05) in our fifteen subjects. Statistical analysis was performed using SAS, version 9.0 (SAS Institute, Inc.). Differences in baseline characteristics between males and females were assessed by the Student’s *t* test. The PROC MIXED procedure for an ANOVA for crossover design with two periods was used to compare the effects of the two treatments. A statistically significant level of *P* ≤ 0.05 was applied for all tests and the results presented are means with their standard errors. The influence of body weight, BMI, sex, and waist and hip circumferences on the changes in various metabolic parameters measured in this study was tested by individual entry of terms and interaction terms into the ANOVA model. No residual effects of the first experimental period over the second period were observed for all inflammatory, cardiovascular and lipid markers. Variable serum amyloid A was not normally distributed, so a non-parametric test using a rank transformation was used.

**Results**

**Subjects**

A total of twenty-one insulin-resistant subjects completed the study. Of these, five subjects were excluded from the analysis because they became diabetic during the study, according to the American Diabetes Association criteria and, in addition, one female was pre-menopausal and was excluded from the analysis. The characteristics at baseline for the insulin-resistant subjects (seven male and eight female) are reported in Table 2. No significant differences were observed between males and females in all mean initial characteristics excepted for HDL-cholesterol (*P* = 0.01). All subjects were overweight or obese (BMI 26–39 kg/m²), fourteen subjects (eight female and six male) had abdominal adiposity (waist circumference >94 cm for males and >80 cm for females) and twelve subjects (75%) met the National Heart, Lung, and Blood Institute/American Heart Association criteria for the metabolic syndrome. According to the criteria for CVD risk of the Centers for Disease Control and Prevention and the American Heart Association, five subjects (four male, one female) had baseline hsCRP concentrations <1.0 mg/l (low risk), six (three male, three female) had concentrations between 1 and 3 mg/l (moderate risk) and four females had concentrations ≥3.0 mg/l (high risk). Moreover, seven subjects (three male, four female) had optimal fasting TAG concentrations (<1.3 mmol/l), four subjects (two male, two female) had desirable TAG concentrations (between 1.13 and 1.69 mmol/l) and four subjects (two male, two female) had normal concentrations (between 1.7 and 2.26 mmol/l). Baseline LDL-cholesterol concentrations were optimal (<2.6 mmol/l) for one subject (one male), near or above optimal (2.6–3.3 mmol/l) for five (four male, one female), borderline high (3.4–4.1 mmol/l) for four females, high (4.15–4.9 mmol/l) for three (one male, two female) and very high (≥4.9 mmol/l) for two (one male, one female).

Our subjects were all insulin-resistant. However, among them, ten subjects had hyperinsulinaemia (fasting plasma insulin >90 pmol/l). According to the American Diabetic Association for the Diagnosis and Classification of Diabetes Mellitus, two subjects (one male and one female) had normal glucose tolerance, eight (four male and four female) had impaired fasting glucose (5.6–9.9 mmol/l) and five (two male and three female) had both impaired fasting glucose and impaired glucose tolerance (7.8–11.0 mmol/l; 2 h post 75 g oral glucose tolerance test).

**Anthropometric measures**

Changes in body weight (0.23 (SEM 0.39) kg) for ω-3 PUFA and −0.02 (SEM 0.32) kg for ω-3 PUFA + FG, BMI (0.07 (SEM 0.14) kg/m² for ω-3 PUFA and 0.01 (SEM 0.11) kg/m² for ω-3 PUFA + FG, HDL-c (0.07 (SEM 0.07) mmol/l for ω-3 PUFA and 0.05 (SEM 0.07) mmol/l for ω-3 PUFA + FG, LDL-c (0.05 (SEM 0.06) mmol/l for ω-3 PUFA and 0.04 (SEM 0.06) mmol/l for ω-3 PUFA + FG).

**Table 2. Subject characteristics at baseline**

(Mean values with their standard errors)

|                      | All (n 15) | Male (n 7) | Female (n 8) |
|----------------------|------------|------------|--------------|
|                      | Mean      | SEM        | Mean        | SEM        | Mean      | SEM        |
| Age (years)          | 57.6      | 2.3        | 54.1        | 2.9        | 61.0      | 3.2        |
| Body weight (kg)     | 80.8      | 2.6        | 83.9        | 4.0        | 78.1      | 3.2        |
| BMI (kg/m²)          | 29.7      | 0.9        | 28.4        | 1.0        | 30.9      | 1.5        |
| Waist circumference (cm) | 99.6      | 1.9        | 99.3        | 3.4        | 99.9      | 2.3        |
| Hip circumference (cm) | 108       | 2          | 104         | 3          | 112       | 3          |
| Cholesterol (mmol/l) |            |            |             |            |           |            |
| Total                | 5.60      | 0.31       | 5.26        | 1.44       | 5.89      | 0.34       |
| LDL                  | 3.74      | 0.26       | 3.52        | 1.28       | 3.93      | 0.27       |
| HDL                  | 1.26      | 0.05       | 1.14        | 0.18       | 1.37      | 0.04*      |
| Total TAG (mmol/l)   | 1.29      | 0.11       | 1.29        | 0.46       | 1.29      | 0.16       |
| Total cholesterol:HDL-cholesterol ratio | 4.52 | 0.34 | 4.75 | 1.85 | 4.31 | 0.24 |
| Fasting plasma glucose (mmol/l) | 6.07 | 0.11 | 5.98 | 0.12 | 6.14 | 0.18 |
| 2 h plasma glucose (mmol/l) | 7.65 | 0.45 | 8.07 | 0.88 | 7.29 | 0.37 |
| Fasting plasma insulin (pmol/l) | 87.9 | 17.8 | 107.0 | 33.0 | 69.1 | 12.9 |

* Difference between males and females, *P* = 0.01.
for n-3 PUFA + FG), waist circumference (0.03 (SEM 0.22) cm for n-3 PUFA and 0.47 (SEM 0.36) cm for n-3 PUFA + FG) and hip circumference (−0.07 (SEM 0.4) cm for n-3 PUFA and −0.03 (SEM 0.21) cm for n-3 PUFA + FG) did not differ significantly between the periods.

Macronutrient intake

As shown in Table 3, n-3 PUFA + FG led to an increase in protein intake in males (21 %; \( P = 0.02 \)) and females (12 %; \( P = 0.03 \)) and a decrease in carbohydrate intake in males (−14 %; \( P = 0.01 \)) and females (−13 %; \( P = 0.05 \)) compared with the n-3 PUFA supplement. However, lipid and energy intakes did not differ during the experimentation, and no differences between the treatments were observed for these variables.

Plasma lipid concentrations, and inflammatory and CVD markers

The plasma lipid concentrations as well as the inflammatory and CVD markers of the subjects are presented in Table 4. When all subjects were taken together, there were no differences in the observed changes for all lipid and lipoprotein markers between the n-3 PUFA and n-3 PUFA + FG supplements. Because a sex–treatment interaction was observed on plasma TAG concentrations \( (P = 0.03) \), we further analysed those lipid data in males and females. In males (Fig. 1(a)), 25 and 11 % decreases were observed in TAG concentrations following n-3 PUFA (1.63 (SEM 0.24)–1.22 (SEM 0.18) mm) and n-3 PUFA + FG (1.51 (SEM 0.29)–1.34 (SEM 0.29) mm), respectively. However, no difference was observed between changes induced by the two treatments \( (P = 0.14) \). In females (Fig. 1(b)), an 8 % reduction in TAG was observed after n-3 PUFA (1.36 (SEM 0.11)–1.25 (SEM 0.11) mm), whereas a 23 % reduction was observed after n-3 PUFA + FG (1.49 (SEM 0.13)–1.15 (SEM 0.12) mm), inducing a difference in the changes of TAG between the n-3 PUFA and n-3 PUFA + FG supplements \( (P = 0.04) \).

Changes in concentrations of inflammatory and CVD markers were not different between the two treatments (Table 4). However, a sex–treatment interaction was also observed for serum hsCRP concentrations \( (P = 0.001) \). In males, n-3 PUFA + FG reduced serum hsCRP by 40 % (1.23 (SEM 0.25)–0.74 (SEM 0.18) mg/l) whereas n-3 PUFA increased hsCRP by 13 % (0.89 (SEM 0.16)–1.01 (SEM 0.20) mg/l) (Fig. 2(a)), provoking a difference in hsCRP changes between n-3 PUFA and n-3 PUFA + FG \( (P = 0.03) \). In females, n-3 PUFA + FG increased serum hsCRP by 20 % (2.43 (SEM 0.63)–2.91 (SEM 0.97) mg/l) whereas the n-3 PUFA supplement induced a 6 % reduction only (2.53 (SEM 0.57)–2.39 (SEM 0.84) mg/l) (Fig. 2(b)). There was thus no difference between hsCRP changes induced by the two treatments in females \( (P = 0.69) \). In the present study, there was a sex–treatment interaction on monocyte chemotactic protein-1 \( (P = 0.04) \) but because it was attributed to two hyper-responders to the n-3 PUFA supplement, it does not seem to be of biological relevance in this study.

| Table 3. Daily dietary macronutrient intakes of males and females throughout the experimental periods (Mean values with their standard errors) |
| --- |
| **Nutrient Intakes** | **Male (n 8)** | **Female (n 8)** |
| **Pre** | **Post** | **Pre** | **Post** |
| **Energy (kJ)** | Mean (SEM) | 10137 (1527) | 9159 (1490) | 9678 (1406) | 10514 (1251) |
| **Protein (% en)** | Mean (SEM) | 15.4 (0.5) | 15.3 (0.5) | 15.5 (0.5) | 14.9 (0.5) |
| **Carbohydrate (% en)** | Mean (SEM) | 60.1 (1.3) | 59.4 (1.3) | 60.4 (1.3) | 59.7 (1.3) |
| **Lipid (% en)** | Mean (SEM) | 29.8 (1.3) | 31.1 (1.3) | 28.0 (1.3) | 30.8 (1.3) |
| **SFA (g)** | Mean (SEM) | 21.6 (0.8) | 21.1 (0.8) | 21.5 (0.8) | 21.0 (0.8) |
| **MUFA (g)** | Mean (SEM) | 31.4 (0.8) | 31.2 (0.8) | 31.8 (0.8) | 30.7 (0.8) |
| **PUFA (g)** | Mean (SEM) | 17.6 (0.8) | 17.7 (0.8) | 17.7 (0.8) | 17.7 (0.8) |
| **Fibre (g)** | Mean (SEM) | 25.0 (0.8) | 25.1 (0.8) | 24.7 (0.8) | 24.8 (0.8) |

FG, fish gelatine; en, energy. P values refer to comparisons between changes induced by the n-3 PUFA and n-3 PUFA + FG treatments (ANOVA for crossover design with two periods).
Table 4. Concentrations of blood lipids, inflammatory and CVD markers before (pre) and after (post) consuming n-3 PUFA and n-3 PUFA + fish gelatine (FG) for 8 weeks in insulin-resistant males and females*
(Mean values with their standard errors)

|                      | n-3 PUFA (n 15) |                      |                      | n-3 PUFA + FG (n 15) |                      |                      |
|----------------------|-----------------|----------------------|----------------------|----------------------|----------------------|----------------------|
|                      | Pre             | Post                | Δ                    | Pre                  | Post                | Δ                    |
|                      | Mean SEM        | Mean SEM            | Mean SEM            | Mean SEM            | Mean SEM            | Mean SEM            |
| Blood lipids (mm)    |                 |                      |                      |                      |                      |
| Total cholesterol    | 5.78 0.34       | 5.55 0.28           | −0.23 0.12           | 5.45 0.28            | 5.41 0.30           | −0.04 0.10           |
|                     | (Mean values with their standard errors) | China | Country | n |                              |                      |                      |
| TAG                  | 1.49 0.13       | 1.23 0.10           | −0.26 0.10           | 1.50 0.15            | 1.24 0.13           | −0.26 0.10           |
| HDL-cholesterol      | 1.07 0.04       | 1.12 0.05           | 0.05 0.03            | 1.03 0.05            | 1.13 0.06           | 0.09 0.03            |
| LDL-cholesterol      | 4.03 0.30       | 3.87 0.26           | −0.16 0.08           | 3.73 0.23            | 3.72 0.26           | −0.02 0.09            |
| Total cholesterol/HDL-cholesterol ratio | 5.54 0.47     | 5.12 0.40           | −0.42 0.13           | 5.46 0.44            | 5.00 0.45           | −0.46 0.10            |

Inflammatory and CVD markers

|                      |                 |                      |                      |                      |                      |
| MCP-1 (pg/ml)*       | 672 42          | 685 46               | 13 53                | 597 58               | 651 42               | 54 46 0.17           |
| hTNF-α (pg/ml)*      | 6.83 1.41       | 5.88 0.71            | −0.96 0.88           | 4.92 0.50            | 5.34 0.49            | 0.42 0.45 0.23 |
| hscCRP (mg/l)*       | 1.64 0.36       | 1.65 0.43            | 0.00 0.21            | 1.78 0.35            | 1.74 0.54            | −0.04 0.31 0.81 |
| IL-1α (pg/ml)        | 116 8           | 115 11               | −1 8                 | 120 9                | 114 7                | −6 6 0.65           |
| IL-6 (pg/ml)         | 123.6 39.7      | 86.8 28.7            | −36.8 39.0           | 105.9 30.8           | 63.0 25.5            | −42.9 31.1 0.99 |
| PAI-1 (ng/ml)        | 2.49 0.45       | 3.69 0.74            | 1.20 0.65            | 1.96 0.47            | 3.41 0.54            | 1.45 0.37 0.76 |
| Adiponectin (μg/ml)  | 14.1 1.3        | 14.7 1.6             | 0.56 0.73            | 14.3 1.4             | 14.2 1.57            | −0.06 0.51 0.42 |
| Homocysteine (μmol/l) | 10.24 0.45     | 9.69 0.46            | −0.55 0.39           | 9.57 0.58            | 9.93 0.43            | 0.36 0.46 0.12 |
| Leptin (ng/ml)       | 16.2 2.7        | 14.8 2.5             | −1.4 1.0             | 17.7 3.7             | 15.9 2.7             | −1.8 2.0 0.79 |
| Cystatin C (mg/l)    | 0.76 0.03       | 0.73 0.03            | −0.03 0.01           | 0.73 0.03            | 0.71 0.03            | −0.02 0.02 0.62 |
| Resistin (ng/ml)     | 25.5 2.5        | 37.2 4.6             | 11.8 3.0             | 26.5 2.6             | 33.7 4.10            | 7.2 3.5 0.32 |
| Serum amyloid A (μg/ml) | 84.6 37.3     | 50.3 6.5             | −34.3 37.1           | 113.9 60.7           | 65.3 11.0            | −48.6 62.0 0.35 |
| Myeloperoxidase (pg/ml) | 40.8 11.6   | 79.1 29.4            | −38.3 19.4           | 43.0 9.0             | 65.5 15.9            | 22.5 15.9 0.42 |
| ADMA* (μg/l)         | 86.5 2.6        | 112.2 14.8           | 25.7 14.4            | 82.9 4.4             | 98.9 10.8            | 15.9 11.6 0.47 |

MCP-1, monococyte chemotactic protein-1; hCRP, highly sensitive C-reactive protein; IL-1ra, IL-1 receptor antagonist; PAI-1, plasminogen activator inhibitor 1; ADMA, asymmetric dimethylarginine.

* n 14 for ADMA, MCP-1 and TNF-α, n 13 for hCRP.
† P values refer to comparisons between changes induced by the n-3 PUFA and n-3 PUFA + FG treatments (ANOVA for crossover design with two periods).

Discussion

The present free-living study investigated the effects of 8-week interventions with n-3 PUFA and FG on lipid profile and inflammatory and CVD markers in males and females with insulin resistance, a population with a known risk for CVD. The marine n-3 PUFA supplement was used as the control. The main findings of the study are that FG may enhance the lipid-lowering effect of fish n-3 PUFA in females and counteract the effect of n-3 PUFA on plasma hCRP in males. The concept that n-3 PUFA and fish protein could induce combined reducing effects on TAG levels has emerged from an animal study(18), but few studies have examined these effects on blood lipid profile in human subjects. Because it has been shown that plasma TAG is one of the strongest predictors for the risk of atherosclerosis and cardiovascular events in subjects with and without CVD, this marker was chosen as the primary endpoint in the present study. Note that our study had a posteriori power of 70–80 % to detect a 20 % decrease in plasma TAG concentrations. This percentage decrease was considered relevant because optimisation of nutrition-related practices recommended by the American Heart Association can result in a marked TAG-lowering effect that ranges between 20 and 50 %.(35)

Fish oil consumption has well-documented and potent TAG-lowering effects(25). A comparable dose of n-3 PUFA to the one used in the present study (1.8 g/d) has been shown to reduce plasma fasting TAG by approximately 20 % (28-d intervention)(37). In the present study, an average 17 % decrease in plasma TAG was observed in response to the n-3 PUFA treatment in our fifteen subjects. In males, the n-3 PUFA supplementation decreased TAG concentrations by 25 %, whereas in females, it decreased TAG by only 8 %. These results are in good agreement with those of the FINGEN Study(38), showing a sex–treatment interaction in 312 adults aged 20–70 years consuming a moderate EPA/DHA (1.8 g EPA–DHA/d) in a double-blind placebo-controlled crossover study for an 8-week intervention period. As in the present study, the FINGEN Study indicated a greater TAG-lowering action of n-3 PUFA in males than in females.

It is well accepted that dietary protein intake contributes more strongly than carbohydrate or fat intake to short-term satiety which, in turn, can have reducing effects on energy intake, body weight and plasma lipids, although data in human subjects are still inconclusive(6,9). In this study, an increase in consumed energy from protein and a decrease in energy intake from carbohydrate in both males and females were observed with FG supplementation without a change in the total energy intake, body weight, BMI and waist circumference. No changes were observed in fibre intake, a nutrient known to affect satiety and energy intake(3). There is thus a possibility that the effect upon satiety and energy adjustment of dietary protein in liquid form may evoke weaker satiety signals than in the solid form because of more rapid stomach emptying and transit of fluids through the digestive tract(46).

Wolfe & Piche(41) and Wolfe & Giovannetti(42) have reported that the replacement of dietary carbohydrate by
protein could lower plasma TAG, but in the present study, the reducing effect of this substitution on TAG was observed in females only. The present results thus indicate that the consumption of n-3 PUFA with or without FG reduced plasma TAG, and the magnitude of response depended on the treatment and on sex. Indeed in the present study, females had significantly lower plasma TAG following n-3 PUFA + FG (−23%) than n-3 PUFA (−8%) (P = 0.04). By contrast, males had a more pronounced plasma TAG reduction following n-3 PUFA (−25%) than n-3 PUFA + FG (−11%), albeit without reaching the level of significance. The higher variability of TAG changes and the low number of subjects could explain the absence of significant differences between the two treatments in males. According to Hokanson & Austin(43), reductions in moderately elevated TAG levels decrease cardiovascular risk more in females than in males. Nevertheless, the marked TAG-lowering response either to n-3 PUFA in males or to n-3 PUFA + FG in females was in good agreement with the 20–50% TAG reduction expected from American Heart Association nutritional recommendations(45). These results suggest that n-3 PUFA in males and n-3 PUFA + FG in females can be effective in helping to reduce plasma TAG.

The TAG-lowering response to FG in females and not in males is consistent with the results of previous human studies showing a decreasing effect of lean white fish diet on TAG metabolism in pre-menopausal(12) and post-menopausal females(13), but not in normolipidaemic males(14). The observed TAG sex-dependent response in the present study could be associated with an increase of sex hormone-binding globulin following the consumption of fish protein in post-menopausal females(13). Increased testosterone and decreased sex hormone-binding globulin have been linked to adverse cardiovascular risk factors, such as adiposity, increased TAG and decreased HDL levels in both pre-menopausal and post-menopausal females(44). Furthermore, lower sex hormone-binding globulin levels predict non-insulin-dependent diabetes mellitus in females but not in males(45). Additionally, a previous study conducted in our laboratory demonstrated that fish protein can reduce insulin resistance(11). Thus, the present results suggest that the divergent effects of FG supplementation on plasma TAG between males and females may be mediated by variations in the status of plasma sex hormones, which are related to glucose tolerance and insulin sensitivity. Further studies on the mechanisms involved in the hypotriacylglycerolaemic effects of FG in females are needed.

FG per se could also have modulated plasma TAG levels in the present study. Our data are in line with those of Saito et al.(21) who reported a decrease in plasma TAG concentrations in rats fed hydrolysates of skin collagen. They
observed that TAG levels were inversely correlated with plasma total hydroxyproline, total glycine and total proline concentrations, three major amino acids derived from low-molecular-weight collagen fish peptides (21). Hafari et al. (46) and Ratnayake et al. (47) have also reported a decrease in TAG levels following a diet rich in glycine in rats fed a high-sucrose diet, suggesting that glycine could have contributed to the observed TAG-lowering effects following the consumption of the FG broth in this study. The lower lysine:arginine ratio of fish protein and gelatine compared with casein may also have been involved (48). Moreover based on studies on fish protein in rats (18) and rabbits (49), there is a possibility that FG per se may have contributed to decrease plasma TAG by increasing lipoprotein lipase activity.

Apart from the primary endpoint, inflammatory and other CVD markers (hsCRP, TNF-α, IL-6, adiponectin and others) were assessed. Our data showed a sex–treatment interaction for hsCRP (P = 0.001). In males, while n-3 PUFA increased plasma hsCRP concentrations by 13 %, n-3 PUFA + FG reduced these levels by 40 %. This reduction was considered to be of biological significance because, on average, the CVD risk based on plasma C-reactive protein concentrations decreased from moderate to low risk in males (34). The C-reactive protein-lowering effect of FG in males is consistent with our previous observations showing that short-term consumption of cod protein compared with other animal proteins led to a decrease in hsCRP in insulin-resistant subjects, mostly males (16). However, in the present study, the serum hsCRP concentration was increased in females by 20 % following n-3 PUFA + FG and decreased by 6 % following n-3 PUFA.

There is, however, one limitation that needs to be addressed regarding the present study. This limitation concerns the absence of no intervention and FG treatments to clearly highlight the effects of FG. Although it has already been shown that fish protein and fish oil have independent and additive effects on plasma TAG in rats (18) and thus that n-3 PUFA supplement can be used as the control group, firm conclusions in this respect cannot be drawn in the present human study. Therefore, in this study, the findings cannot be generalised beyond the comparison between the effects of marine n-3 PUFA and those of n-3 PUFA plus FG.

In conclusion, our data showed that, in free-living conditions, FG supplementation and a concomitant decrease in carbohydrate intake enhanced the lipid-lowering effect of n-3 PUFA supplementation in insulin-resistant females, and beneficially counteracted the effect of n-3 PUFA on plasma C-reactive protein in insulin-resistant males. These results suggest that FG may exert a beneficial effect on CVD risk by lipid-lowering and anti-inflammatory effects in free-living conditions.
insulin-resistant females and males, respectively. Further studies are needed to elucidate the physiological mechanisms underlying the divergent effects of n-3 PUFA and FG on TAG and hsCRP levels between males and females, and to identify specific bioactive peptides and amino acids that contribute to these effects.

Acknowledgements

This research was supported by a grant from The Advanced Foods and Materials Network. There are no conflicts of interest in this research. Ocean Nutrition Canada provided marine n-3 PUFA capsules, and Norland Products provided fish gelatin. The authors thank Simon Pelletier, Patricia Pelletier, Marc Majaron, Marie-Élise Carbonneau and Nadine Leblanc for technical and skillful assistance. As to the contribution of each author to the manuscript, H. J. designed the experiment and discussed the experimental results with all the other co-authors, supervised E. P. D. and J. B. and assisted E. P. D. in writing the manuscript. S. J. W. helped in designing the experiment, was responsible for the medical follow-up of the participants and discussed the experimental results. As graduate students, E. P. D. and J. B. carried out the experiment under the supervision of H. J., S. J. W., J. M. and C. L. and discussed the experimental results. As a research coordinator, J. M. helped in designing the study and the experiment plan, supervised and advised E. P. D. and J. B. on recruitment and nutritional aspects of the experiment, and discussed the experimental results. C. L. and A. M. helped E. P. D. to carry out measurements of inflammatory markers and to interpret data during the experiment. As a doctoral student, E. C. supervised by J. S. H. helped E. P. D. to carry out measurements of cardiovascular markers. E. C., J. S. H. and J. F. discussed the experimental results and supervised E. P. D.’s training in their laboratory. B. H. helped in designing the study and to interpret the data.

References

1. Schenk S, Saberi M & Olefsky JM (2008) Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118, 2992–3002.
2. Harris WS, Michael M, Ann PT, et al. (2008) Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Altern Med Rev 13, 12–24.
3. Calder PC (2006) n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83, 1505S–1519S.
4. Schacky C (2007) n-3 PUFA in CVD: influence of cytokine polymorphism. Pro Nutr Sci 66, 166–170.
5. Varga-Lopez S, Kaul N, Devaraj S, et al. (2004) Supplementation with omega-3 polyunsaturated fatty acids and all-α-α-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers. Metabolism 53, 236–240.
6. Mori TA, Woodman RJ, Burke V, et al. (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radical Biol Med 35, 772–781.
7. Klein S, Sheard NF, Pi-Sunyer X, et al. (2004) Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Am J Clin Nutr 80, 257–263.
8. Westerterp-Plantenga MS, Nieuwenhuizen A, Tome D, et al. (2009) Dietary protein, weight loss, and weight maintenance. Annu Rev Nutr 29, 21–41.
9. Halon LT & Hu FB (2004) The effects of high protein diets on thermogenesis, satiety and weight loss: a critical review. J Am Coll Nutr 23, 373–385.
10. Lavigne C, Tremblay F, Asselin G, et al. (2001) Prevention of skeletal muscle insulin resistance by dietary cod protein in high fat-fed rats. Am J Physiol Endocrinol Metab 281, E62–E71.
11. Ouadlet V, Marois J, Weisnagel SJ, et al. (2007) Dietary cod protein improves insulin sensitivity in insulin-resistant men and women. Diabetes Care 30, 2816–2821.
12. Gascon A, Jacques H, Moorjani S, et al. (1996) Plasma lipoprotein profile and lipolytic activities in response to the substitution of lean white fish for other animal protein sources in premenopausal women. Am J Clin Nutr 63, 315–321.
13. Jacques H, Noreau L & Moorjani S (1992) Effects on plasma lipoproteins and endogenous sex hormones of substituting lean white fish for other animal protein sources in diets of postmenopausal women. Am J Clin Nutr 55, 896–901.
14. Lacaille B, Julien P, Deshaies Y, et al. (2000) Responses of plasma lipoproteins and sex hormones to the consumption of lean fish incorporated in a prudent-type diet in normolipidemic men. J Am Coll Nutr 19, 745–753.
15. Beauchesne-Rondeau E, Gascon A, Bergeron J, et al. (2003) Plasma lipids and lipoproteins in hypercholesterolemic men fed a lipid-lowering diet containing lean beef, lean fish, or poultry. Am J Clin Nutr 77, 587–593.
16. Ouadlet V, Weisnagel J, Marois J, et al. (2008) Dietary cod protein reduces plasma C-reactive protein in insulin-resistant men and women. J Nutr 138, 2386–2391.
17. Pot GK, Greeden A & Majak-Newman G (2010) Increased consumption of fatty and lean fish reduces serum C-reactive protein concentrations but not inflammation markers in feces and in colonic biopsies. J Nutr 140, 371–376.
18. Demony I, Deshaies Y, Lamarche B, et al. (2003) Cod protein lowers the hepatic triglyceride secretion rate in rats. J Nutr 133, 1398–1402.
19. Karim AA & Bhat R (2009) Fish gelatin: properties, challenges, and prospects as an alternative to mammalian gelatins. Food Hydrocoll 23, 563–576.
20. Bello AE & Oesser S (2006) Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature. Curr Med Res Opin 22, 2221–2232.
21. Saito M, Kiyose C, Higuchi T, et al. (2009) A comprehensive view of the physiological mechanisms underlying the divergent effects of n-3 PUFA and FG on TAG and hsCRP levels between males and females, and to identify specific bioactive peptides and amino acids that contribute to these effects.
22. Wu J, Fujikawa M, Sugimoto K, et al. (2004) Assessment of effectiveness of oral administration of collagen peptides on bone metabolism in growing and mature rats. J Bone Miner Metab 22, 547–553.
23. Shi H & Clegg DJ (2009) Sex differences in the regulation of body weight. Physiol Behav 97, 199–204.
24. Pilote L, Dasgupta K, Guru V, et al. (2007) A comprehensive view of sex-specific issues related to cardiovascular disease. Can Med Assoc J 176, S1–S44.
25. Kahn SE, McCallucho DK & Porte D (1997) Insulin secretion in the male and female rat: sex-specific issues related to cardiovascular disease. Can Med Assoc J 176, S1–S44.
26. American Diabetes Association (2010) Standards of medical care in diabetes (position statement). Diabetes Care 33, S1–S61.
32. Alberti KG, Zimmet P & Shaw J (2006) Metabolic syndrome
33. Grundy SM, Bryan HB, Cleeman JI, Pearson TA, Mensah GA, Alexander RW,
34. Stark KD & Holub BJ (2004) Differential eicosapentaenoic acid
35. Miller M, Stone NJ, Ballantyne C, et al. (1993) Decreased sex
36. DiMeglio DP & Mattes RD (2003) Markers of
37. Haffner SM, Valdez RA, Morales PA, et al. (1993) Decreased sex
38. Caslake MJ, Miles EA, Kotler BM, et al. (2008) Effect of sex and
genotype on cardiovascular biomarker response to fish oils: the
39. Burton-Freeman B (2000) Dietary fiber and energy regulation.
40. Wolfe BM & Giovannetti PM (1991) Short-term effects of substi-
tuting protein for carbohydrate in the diets of moderately hyperch-
olesterolemic human subjects. Metabolism 40, 338–343.
41. Pugeat M, Moulin P, Cousin P, et al. (1986) Plasma triglycerides
42. Hokanson JE & Austin MA (1996) Plasma triglyceride level is a risk
factor for cardiovascular disease independent of high-density lipo-
protein cholesterol level: a meta-analysis of population-based pro-
spective studies. J Cardiovasc Risk 3, 213–219.
43. Hafidi M, Perez I, Zamora J, et al. (2004) Glycine intake decreases
plasma free fatty acids, adipose cell size, and blood pressure in
surcore-fed rats. Am J Physiol Regul Integr Comp Physiol 287,
44. Pfeuffer M & Barth CA (1992) Dietary sucrose but not starch pro-
mutates protein-induced differences in rates of VLDL secretion and
plasma lipid concentrations in rats. J Nutr 122, 1582–1586.
45. Bergeron N, Deshaies Y & Jacques H (1992) Dietary fish protein
modulates high density lipoprotein cholesterol and lipoprotein
lipase activity in rabbits. J Nutr 122, 1731–1737.